CL2017000780A1 - Composiciones y métodos para silenciar la expresión del virus gen de la hepatitis b - Google Patents
Composiciones y métodos para silenciar la expresión del virus gen de la hepatitis bInfo
- Publication number
- CL2017000780A1 CL2017000780A1 CL2017000780A CL2017000780A CL2017000780A1 CL 2017000780 A1 CL2017000780 A1 CL 2017000780A1 CL 2017000780 A CL2017000780 A CL 2017000780A CL 2017000780 A CL2017000780 A CL 2017000780A CL 2017000780 A1 CL2017000780 A1 CL 2017000780A1
- Authority
- CL
- Chile
- Prior art keywords
- compositions
- hepatitis
- expression
- silence
- methods
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 241000700605 Viruses Species 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title abstract 2
- 231100000283 hepatitis Toxicity 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- -1 LIPID ACIDS Chemical class 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000003387 muscular Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462059056P | 2014-10-02 | 2014-10-02 | |
| US201562120149P | 2015-02-24 | 2015-02-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000780A1 true CL2017000780A1 (es) | 2017-11-03 |
Family
ID=54325078
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000780A CL2017000780A1 (es) | 2014-10-02 | 2017-03-31 | Composiciones y métodos para silenciar la expresión del virus gen de la hepatitis b |
Country Status (17)
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5475753B2 (ja) * | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| EP3318248B1 (en) | 2009-12-01 | 2019-04-10 | Translate Bio, Inc. | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| EP2717893B1 (en) | 2011-06-08 | 2019-05-08 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mrna delivery |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| TR201901310T4 (tr) | 2013-03-14 | 2019-02-21 | Translate Bio Inc | Mesajcı RNA'nın saflaştırılması yöntemleri. |
| JP6399560B2 (ja) | 2013-03-14 | 2018-10-03 | トランスレイト バイオ， インコーポレイテッド | ｍＲＮＡによってコードされる抗体を送達するための方法及び組成物 |
| LT2968586T (lt) | 2013-03-14 | 2018-11-26 | Translate Bio, Inc. | Cft mrnr kompozicijos bei su jomis susiję būdai ir panaudojimai |
| DK2972360T3 (en) | 2013-03-15 | 2018-05-22 | Translate Bio Inc | SYNERGISTIC IMPROVEMENT OF DELIVERY OF NUCLEIC ACIDS THROUGH MIXED FORMULATIONS |
| EP3574923A1 (en) | 2013-10-22 | 2019-12-04 | Translate Bio, Inc. | Mrna therapy for phenylketonuria |
| BR112016009014B1 (pt) | 2013-10-22 | 2024-02-06 | Translate Bio, Inc | USO DE COMPOSIÇÃO COMPREENDENDO mRNA PARA DEFICIÊNCIA DE ARGININOSSUCINATO SINTETASE |
| CN105658800A (zh) | 2013-10-22 | 2016-06-08 | 夏尔人类遗传性治疗公司 | Mrna的cns递送及其用途 |
| CN112618732A (zh) | 2013-10-22 | 2021-04-09 | 夏尔人类遗传性治疗公司 | 用于递送信使rna的脂质制剂 |
| KR102739894B1 (ko) | 2014-04-25 | 2024-12-05 | 샤이어 휴먼 지네틱 테라피즈 인크. | 메신저 rna 의 정제 방법 |
| US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| CN111588695A (zh) | 2014-06-24 | 2020-08-28 | 川斯勒佰尔公司 | 用于递送核酸的立体化学富集组合物 |
| BR112016030852A2 (pt) | 2014-07-02 | 2018-01-16 | Shire Human Genetic Therapies | encapsulação de rna mensageiro |
| WO2016090262A1 (en) | 2014-12-05 | 2016-06-09 | Shire Human Genetic Therapies, Inc. | Messenger rna therapy for treatment of articular disease |
| AU2016233135B2 (en) | 2015-03-19 | 2021-07-08 | Translate Bio, Inc. | mRNA therapy for pompe disease |
| US20170016000A1 (en) | 2015-07-17 | 2017-01-19 | Arcturus Therapeutics, Inc. | Compositions and agents against hepatitis b virus and uses thereof |
| US20170137821A1 (en) | 2015-07-17 | 2017-05-18 | Arcturus Therapeutics, Inc. | Molecules and agents for treating hepatitis b virus |
| WO2017019891A2 (en) * | 2015-07-29 | 2017-02-02 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis b virus gene expression |
| CA3001852A1 (en) | 2015-10-14 | 2017-04-20 | Translate Bio, Inc. | Modification of rna-related enzymes for enhanced production |
| WO2017177169A1 (en) | 2016-04-08 | 2017-10-12 | Rana Therapeutics, Inc. | Multimeric coding nucleic acid and uses thereof |
| EP3842530A1 (en) | 2016-06-13 | 2021-06-30 | Translate Bio, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| AU2017353986B2 (en) * | 2016-11-07 | 2021-08-19 | Arbutus Biopharma Corporation | Substituted pyridinone-containing tricyclic compounds, and methods using same |
| JP7325327B2 (ja) * | 2016-12-21 | 2023-08-14 | アルブータス・バイオファーマー・コーポレイション | インフュージョンリアクションを改善するための方法 |
| EP3585417B1 (en) | 2017-02-27 | 2023-02-22 | Translate Bio, Inc. | Method of making a codon-optimized cftr mrna |
| CA3063531A1 (en) | 2017-05-16 | 2018-11-22 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr |
| TW201919653A (zh) * | 2017-06-16 | 2019-06-01 | 加拿大商艾爾布圖斯生技公司 | 用於治療ｂ型肝炎之治療組合物及方法 |
| CN109101120B (zh) * | 2017-06-21 | 2021-09-28 | 腾讯科技（深圳）有限公司 | 图像显示的方法和装置 |
| WO2019051257A2 (en) * | 2017-09-11 | 2019-03-14 | Arbutus Biopharma Corporation | METHODS OF TREATING HEPATITIS B TYPE INFECTIONS |
| CR20210262A (es) | 2017-10-16 | 2022-06-27 | Hoffmann La Roche | MOLÉCULA DE ÁCIDOS NUCLEICOS PARA LA REDUCCIÓN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÓN DE LA HEPATITIS B (DIVISIONAL DEL EXPEDIENTE 2020-0205) |
| MA51306A (fr) | 2017-12-20 | 2020-10-28 | Translate Bio Inc | Compositions et procédés améliorés pour le traitement du déficit en ornithine transcarbamylase |
| TWI801517B (zh) | 2018-03-12 | 2023-05-11 | 加拿大商愛彼特生物製藥公司 | 經取代的2-吡啶酮三環化合物、其類似物及其使用方法 |
| RU2020135289A (ru) * | 2018-04-05 | 2022-05-05 | Ф. Хоффманн-Ля Рош Аг | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в |
| JP2021521154A (ja) | 2018-04-12 | 2021-08-26 | アービュタス バイオファーマ コーポレイション | 置換ピリジノン含有三環式化合物を調製するための方法 |
| CA3108544A1 (en) | 2018-08-24 | 2020-02-27 | Translate Bio, Inc. | Methods for purification of messenger rna |
| US20210395751A1 (en) * | 2018-10-31 | 2021-12-23 | The University Of Sydney | Compositions and methods for treating viral infections |
| WO2020097540A1 (en) | 2018-11-09 | 2020-05-14 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
| AU2019377131A1 (en) * | 2018-11-09 | 2021-06-03 | Arbutus Biopharma Corporation | Lipid nanoparticle formulations |
| CA3120647A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
| WO2020136149A1 (en) | 2018-12-24 | 2020-07-02 | Selexis Sa | Characterization and inactivation of endogenous retroviruses in chinese hamster ovary cells |
| US20230046668A1 (en) | 2019-12-24 | 2023-02-16 | Selexis S.A. | Targeted integration in mammalian sequences enhancing gene expression |
| RU2733361C1 (ru) * | 2020-07-14 | 2020-10-01 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Средство для ингибирования репликации вируса SARS-CoV-2, опосредованного РНК-интерференцией |
| RU2746362C9 (ru) * | 2021-03-11 | 2021-04-26 | Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России (ФГБУ "ГНЦ Институт иммунологии" ФМБА России) | Комбинированное лекарственное средство, обладающее противовирусным эффектом в отношении нового коронавируса SARS-CoV-2 |
Family Cites Families (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3993754A (en) | 1974-10-09 | 1976-11-23 | The United States Of America As Represented By The United States Energy Research And Development Administration | Liposome-encapsulated actinomycin for cancer chemotherapy |
| US4086257A (en) | 1976-10-12 | 1978-04-25 | Sears Barry D | Phosphatidyl quaternary ammonium compounds |
| CH624011A5 (cg-RX-API-DMAC7.html) | 1977-08-05 | 1981-07-15 | Battelle Memorial Institute | |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4522803A (en) | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
| US4588578A (en) | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5286634A (en) | 1989-09-28 | 1994-02-15 | Stadler Joan K | Synergistic method for host cell transformation |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| WO1993023011A1 (en) | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
| US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
| US5426039A (en) | 1993-09-08 | 1995-06-20 | Bio-Rad Laboratories, Inc. | Direct molecular cloning of primer extended DNA containing an alkane diol |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US5908635A (en) | 1994-08-05 | 1999-06-01 | The United States Of America As Represented By The Department Of Health And Human Services | Method for the liposomal delivery of nucleic acids |
| CA2200952C (en) | 1994-09-30 | 2006-04-11 | Inex Pharmaceuticals Corp. | Novel compositions comprising quaternary ammonium compounds and neutral lipids for the introduction of polyanionic materials into cells |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| US5753613A (en) | 1994-09-30 | 1998-05-19 | Inex Pharmaceuticals Corporation | Compositions for the introduction of polyanionic materials into cells |
| US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US5756122A (en) | 1995-06-07 | 1998-05-26 | Georgetown University | Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| AU723163B2 (en) | 1995-06-07 | 2000-08-17 | Tekmira Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| IL115199A (en) | 1995-09-07 | 2005-05-17 | Opperbas Holding Bv | Composition comprising a polynucleic acid molecule in a liposome and method using said composition |
| US6620805B1 (en) | 1996-03-14 | 2003-09-16 | Yale University | Delivery of nucleic acids by porphyrins |
| US6756054B1 (en) | 1996-05-24 | 2004-06-29 | Ic-Vec Limited | Polycationic sterol derivatives as transfection agents |
| DE69725878T2 (de) | 1996-08-13 | 2004-07-29 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Zusammensetzungen zur polynukleotidabgabe |
| US6126965A (en) | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| DE69841002D1 (de) | 1997-05-14 | 2009-09-03 | Univ British Columbia | Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln |
| DE69834038D1 (de) | 1997-07-01 | 2006-05-18 | Isis Pharmaceutical Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| US6110745A (en) | 1997-07-24 | 2000-08-29 | Inex Pharmaceuticals Corp. | Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method |
| US6320017B1 (en) | 1997-12-23 | 2001-11-20 | Inex Pharmaceuticals Corp. | Polyamide oligomers |
| US7091192B1 (en) | 1998-07-01 | 2006-08-15 | California Institute Of Technology | Linear cyclodextrin copolymers |
| US6509323B1 (en) | 1998-07-01 | 2003-01-21 | California Institute Of Technology | Linear cyclodextrin copolymers |
| ATE237312T1 (de) | 1998-07-20 | 2003-05-15 | Protiva Biotherapeutics Inc | In liposomen verkapselte nukleinsäurekomplexe |
| US7479276B1 (en) | 1999-02-22 | 2009-01-20 | Synergene Therapeutics, Inc. | Antibody fragment-targeted immunoliposomes for systemic gene delivery |
| EP1173600A2 (en) | 1999-04-20 | 2002-01-23 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| US6852334B1 (en) | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US7098032B2 (en) | 2001-01-02 | 2006-08-29 | Mirus Bio Corporation | Compositions and methods for drug delivery using pH sensitive molecules |
| US6200599B1 (en) | 1999-10-07 | 2001-03-13 | The Regents Of The University Of California | Ortho ester lipids |
| US20050037086A1 (en) | 1999-11-19 | 2005-02-17 | Zycos Inc., A Delaware Corporation | Continuous-flow method for preparing microparticles |
| WO2001072283A1 (en) | 2000-03-29 | 2001-10-04 | Aradigm Corporation | Cationic liposomes |
| US7189705B2 (en) | 2000-04-20 | 2007-03-13 | The University Of British Columbia | Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers |
| AU6815901A (en) | 2000-06-02 | 2001-12-17 | Zycos Inc | Delivery systems for bioactive agents |
| US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
| US7427394B2 (en) | 2000-10-10 | 2008-09-23 | Massachusetts Institute Of Technology | Biodegradable poly(β-amino esters) and uses thereof |
| US7053150B2 (en) | 2000-12-18 | 2006-05-30 | Nektar Therapeutics Al, Corporation | Segmented polymers and their conjugates |
| TW593427B (en) | 2000-12-18 | 2004-06-21 | Nektar Therapeutics Al Corp | Synthesis of high molecular weight non-peptidic polymer derivatives |
| TWI321054B (en) | 2000-12-19 | 2010-03-01 | California Inst Of Techn | Compositions containing inclusion complexes |
| AU2002305094B2 (en) | 2001-03-26 | 2007-01-11 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| WO2002076427A2 (en) | 2001-03-26 | 2002-10-03 | Thomas Jefferson University | Ph sensitive liposomal drug delivery |
| US20030026831A1 (en) | 2001-04-20 | 2003-02-06 | Aparna Lakkaraju | Anionic liposomes for delivery of bioactive agents |
| US20030203865A1 (en) | 2001-04-30 | 2003-10-30 | Pierrot Harvie | Lipid-comprising drug delivery complexes and methods for their production |
| US20030077829A1 (en) | 2001-04-30 | 2003-04-24 | Protiva Biotherapeutics Inc.. | Lipid-based formulations |
| DE10127526A1 (de) | 2001-05-31 | 2002-12-12 | Novosom Ag | Verfahren zur Herstellung und Auflösung von Nano- und Mikrokapseln |
| US7063860B2 (en) | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| US7101995B2 (en) | 2001-08-27 | 2006-09-05 | Mirus Bio Corporation | Compositions and processes using siRNA, amphipathic compounds and polycations |
| DE10152145A1 (de) | 2001-10-19 | 2003-05-22 | Novosom Ag | Stabilisierung von Liposomen und Emulsionen |
| US20030157030A1 (en) | 2001-11-02 | 2003-08-21 | Insert Therapeutics, Inc. | Methods and compositions for therapeutic use of rna interference |
| DE10157046A1 (de) | 2001-11-18 | 2003-06-12 | Novosom Ag | Nano- und Mikrokapseln umfassend Reaktivpolymere |
| WO2003057190A1 (en) | 2001-12-31 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Efficient nucleic acid encapsulation into medium sized liposomes |
| US20060058249A1 (en) | 2002-01-09 | 2006-03-16 | Shangguan Tong | Efficient nucleic acid encapsulation into medium sized liposomes |
| US20060051315A1 (en) | 2002-02-01 | 2006-03-09 | Scaria Puthupparampil V | Polymers for delivering peptides and small molecules in vivo |
| DE10207177A1 (de) | 2002-02-19 | 2003-09-04 | Novosom Ag | Fakultativ kationische Lipide |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| EP1476492A1 (en) | 2002-02-22 | 2004-11-17 | Insert Therapeutics Inc. | Carbohydrate-modified polymers, compositions and uses related thereto |
| US7037520B2 (en) | 2002-03-22 | 2006-05-02 | Baylor College Of Medicine | Reversible masking of liposomal complexes for targeted delivery |
| US20030198664A1 (en) | 2002-03-29 | 2003-10-23 | Sullivan Sean Michael | Lipid mediated screening of drug candidates for identification of active compounds |
| EP1507561B1 (en) | 2002-05-24 | 2009-07-15 | Mirus Bio Corporation | Compositions for delivering nucleic acids to cells |
| DE60335186D1 (de) | 2002-06-20 | 2011-01-13 | Cytos Biotechnology Ag | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung |
| EP2338478B1 (en) | 2002-06-28 | 2014-07-23 | Protiva Biotherapeutics Inc. | Method for producing liposomes |
| US7682626B2 (en) | 2003-02-07 | 2010-03-23 | Roche Madison Inc. | Polyvinylethers for delivery of polynucleotides to mammalian cells |
| JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| JP4842821B2 (ja) | 2003-09-15 | 2011-12-21 | プロチバ バイオセラピューティクス インコーポレイティッド | ポリエチレングリコール修飾脂質化合物およびその使用 |
| US7745651B2 (en) | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| AU2005252273B2 (en) | 2004-06-07 | 2011-04-28 | Arbutus Biopharma Corporation | Lipid encapsulated interfering RNA |
| US7883688B2 (en) | 2005-02-03 | 2011-02-08 | Agency For Science, Technology And Research | Polycationic polyrotaxanes capable of forming complexes with nucleic acids |
| WO2007086881A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| EP1937213B1 (en) | 2005-07-27 | 2017-10-25 | Protiva Biotherapeutics Inc. | Systems and methods for manufacturing liposomes |
| CN105030654A (zh) | 2006-10-03 | 2015-11-11 | 阿尔尼拉姆医药品有限公司 | 含脂质的制品 |
| KR101629017B1 (ko) | 2007-05-22 | 2016-06-10 | 아크투루스 쎄라퓨틱스, 인크. | 히드록시메틸 치환된 ｒｎａ 올리고뉴클레오티드 및 ｒｎａ 복합체 |
| EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
| JP5475753B2 (ja) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| WO2010006282A2 (en) | 2008-07-10 | 2010-01-14 | Serina Therapeutics, Inc. | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
| CA2744093A1 (en) | 2008-12-03 | 2010-06-10 | Marina Biotech, Inc. | Una oligomer structures for therapeutic agents |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| WO2011139710A1 (en) | 2010-04-26 | 2011-11-10 | Marina Biotech, Inc. | Nucleic acid compounds with conformationally restricted monomers and uses thereof |
| HUE044815T2 (hu) * | 2010-08-17 | 2019-11-28 | Sirna Therapeutics Inc | Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával |
| WO2013003520A1 (en) | 2011-06-30 | 2013-01-03 | Arrowhead Research Corporation | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
-
2015
- 2015-10-01 BR BR112017006679A patent/BR112017006679A2/pt not_active Application Discontinuation
- 2015-10-01 CR CR20170174A patent/CR20170174A/es unknown
- 2015-10-01 EP EP15781007.8A patent/EP3201338B1/en active Active
- 2015-10-01 US US15/515,952 patent/US10415037B2/en active Active
- 2015-10-01 KR KR1020177011725A patent/KR20170075742A/ko not_active Withdrawn
- 2015-10-01 AU AU2015328012A patent/AU2015328012A1/en not_active Abandoned
- 2015-10-01 WO PCT/US2015/053569 patent/WO2016054421A1/en not_active Ceased
- 2015-10-01 CA CA2963271A patent/CA2963271A1/en not_active Abandoned
- 2015-10-01 JP JP2017517791A patent/JP2017536092A/ja active Pending
- 2015-10-01 CN CN201580062374.9A patent/CN107208095B/zh active Active
- 2015-10-01 SG SG11201702662UA patent/SG11201702662UA/en unknown
- 2015-10-01 RU RU2017114964A patent/RU2017114964A/ru not_active Application Discontinuation
- 2015-10-02 TW TW107110295A patent/TW201900876A/zh unknown
- 2015-10-02 TW TW104132625A patent/TW201623614A/zh unknown
-
2017
- 2017-03-29 IL IL251450A patent/IL251450A0/en unknown
- 2017-03-31 CL CL2017000780A patent/CL2017000780A1/es unknown
- 2017-04-03 PH PH12017500614A patent/PH12017500614A1/en unknown
- 2017-04-27 CO CONC2017/0004290A patent/CO2017004290A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180016583A1 (en) | 2018-01-18 |
| RU2017114964A (ru) | 2018-11-07 |
| CO2017004290A2 (es) | 2017-09-20 |
| SG11201702662UA (en) | 2017-04-27 |
| JP2017536092A (ja) | 2017-12-07 |
| CA2963271A1 (en) | 2016-04-07 |
| BR112017006679A2 (pt) | 2017-12-26 |
| AU2015328012A1 (en) | 2017-05-11 |
| TW201900876A (zh) | 2019-01-01 |
| KR20170075742A (ko) | 2017-07-03 |
| WO2016054421A1 (en) | 2016-04-07 |
| TW201623614A (zh) | 2016-07-01 |
| IL251450A0 (en) | 2017-05-29 |
| RU2017114964A3 (cg-RX-API-DMAC7.html) | 2018-11-07 |
| CN107208095A (zh) | 2017-09-26 |
| CR20170174A (es) | 2017-11-07 |
| EP3201338A1 (en) | 2017-08-09 |
| AU2015328012A2 (en) | 2018-06-14 |
| CN107208095B (zh) | 2021-11-16 |
| US10415037B2 (en) | 2019-09-17 |
| EP3201338B1 (en) | 2021-11-03 |
| PH12017500614A1 (en) | 2017-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000780A1 (es) | Composiciones y métodos para silenciar la expresión del virus gen de la hepatitis b | |
| CY1125368T1 (el) | Εμβολια κατα των ιων του αναπνευστικου συστηματος | |
| CY1125084T1 (el) | Εμβολια νουκλεϊκου οξεος | |
| GT201500020A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CO2017012268A2 (es) | Derivados de sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b | |
| MX2022013010A (es) | Composiciones y metodos para inhibir la expresion genica de lpa. | |
| CR20160237A (es) | Derivados de la carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| EA201792354A1 (ru) | Композиции обетихолевой кислоты и способы применения | |
| EA201890999A1 (ru) | Вакцина против вируса простого герпеса | |
| BR112016020688A2 (pt) | Composições úteis no tratamento da deficiência da ornitina transcarbamilase (otc) | |
| EA201500207A1 (ru) | Гетероароматические соединения в качестве ингибиторов втк | |
| MX2015014816A (es) | Compuestos de microarn y metodos para modular al mir-122. | |
| EA201790700A1 (ru) | Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| MX2014005342A (es) | Inhibidores del virus de la hepatitis c. | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| CO2018004576A2 (es) | Composición farmacéutica que comprende ácidos grasos activados | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| MX2017005861A (es) | Metodos para el control transcripcional objetivo en regiones del super mejorador. | |
| MX380393B (es) | Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas. | |
| EA033264B1 (ru) | Новый тритерпенон по с-3 с обратными амидными производными по с-17 в качестве ингибиторов вич | |
| UY34420A (es) | ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos" | |
| CL2017000707A1 (es) | Derivados de nucleosidos sustituidos de 4'-vinilo como inhibidores de la replicación del arn del virus sincicial respiratorio | |
| BR112018009946A2 (pt) | pró-fármacos de ácido nucleico | |
| BR112017008033A2 (pt) | composição farmacêutica para administração oral e respectivo processo de preparação |